drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, lentiviral-engineered chimeric antigen receptor T-cell therapy with a bicephalic APRIL/BAFF ligand domain enabling dual recognition of BCMA and TACI (and possibly BAFF-R) on malignant plasma cells to trigger T-cell activation and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally engineered to express a chimeric antigen receptor with a bicephalic APRIL/BAFF ligand domain that binds BCMA and TACI (and possibly BAFF-R) on malignant plasma cells. Receptor engagement activates CAR signaling (CD3ζ with costimulation), leading to T‑cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing. Dual targeting is intended to reduce antigen escape compared with single-antigen CARs.
drug_name
APRIL-BAFF-Bicephali CAR-T cells
nct_id_drug_ref
NCT06132711